UC Davis study: Latino smokers in California on Medi-Cal still not getting help needed to quit

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A team of researchers with the UC Davis Comprehensive Cancer Center found that even with expanded access to Medi-Cal health coverage, Latino smokers in California continue to get less help than non-Latino white people quitting smoking.

Results from a cross-sectional study of 1,861 participants, published in JAMA Network Open, highlighted the inequity. 

The Affordable Care Act increased access to Medicaid, which is called Medi-Cal in California. 

By the fall of 2014, 2.8 million more people in the state gained access to Medi-Cal. Of these, 41% were newly insured non-elderly Latinos. The percentage of smokers covered by Medi-Cal increased substantially, from 19.3% before the ACA to 41.5% afterward.

The research shows that Latino smokers on Medi-Cal do not receive the same amount of tobacco cessation advice and assistance that non-Latino white smokers on Medi-Cal receive when they are seen by health professionals.

The lead author of the study, Cindy Valencia, said using strategies to engage tobacco users outside of a clinical encounter, such as proactive outreach and community-based engagement, may help address this disparity.

The study was conducted as part of Valencia’s PhD dissertation in Public Health Sciences. She is the first graduate of the program and a Latina.

Table of Contents

YOU MAY BE INTERESTED IN

Tagrisso (osimertinib) demonstrated a sustained, clinically meaningful overall survival benefit at eight years compared to placebo in the adjuvant treatment of patients with early-stage (1B, 2, and 3A) epidermal growth factor receptor-mutated non-small cell lung cancer after complete tumor resection with curative intent, according to the updated exploratory results from the ADAURA phase III trial. 
Biologic drugs play an important role in treating cancers such as breast cancer and lymphoma, but their high costs can add to the financial burden of cancer care. Now, lower-cost versions known as biosimilars are gaining ground, and a study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center suggests their growing use is associated with lower costs for both insurers and patients.
Hansoh Pharmaceutical Group announced positive overall survival data from ARTEMIS-008, its pivotal phase III trial in China, evaluating the B7-H3-targeted antibody-drug conjugate risvutatug rezetecan (Ris-Rez) versus topotecan in patients with relapsed small cell lung cancer whose disease progressed following platinum-based first-line therapy.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login